Tirzide 7.5 mg (Tirzepatide INN)
Dual GIP & GLP-1 Receptor Agonist for Type 2 Diabetes Management
💊 Pharmacology:
Tirzepatide is a first-in-class dual incretin receptor agonist that activates:
This dual mechanism:
Enhances glucose-dependent insulin secretion
Reduces glucagon levels
Delays gastric emptying
Promotes satiety and weight loss
Improves overall glycemic control
It provides superior HbA1c reduction compared to traditional GLP-1 therapies in many patients.
📌 Indications:
Tirzide® 7.5 mg is indicated for:
Type 2 Diabetes Mellitus as an adjunct to diet and exercise
Patients requiring improved glycemic control
May also support weight management in diabetic patients
Not indicated for Type 1 Diabetes or diabetic ketoacidosis.
💉 Dosage & Administration:
Starting dose: 7.5 mg once weekly (subcutaneous injection)
Dose escalation may occur based on physician recommendation
Administer on the same day each week
Can be taken with or without meals
Injection sites: abdomen, thigh, or upper arm
Follow medical guidance strictly for titration.
⚠️ Precautions & Warnings:
Monitor blood glucose regularly
Risk of gastrointestinal side effects (nausea, vomiting)
Caution in patients with history of pancreatitis
Monitor for hypoglycemia if used with insulin or sulfonylureas
Not recommended in patients with severe gastrointestinal disease
❌ Contraindications:
Hypersensitivity to Tirzepatide
Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
🤰 Pregnancy & Lactation:
Not recommended during pregnancy
Breastfeeding should be avoided during treatment
Effective contraception advised during therapy
⚕️ Side Effects:
Common side effects include:
Nausea
Vomiting
Diarrhea
Decreased appetite
Abdominal discomfort
Injection site reactions
Serious but rare:
🧊 Storage Conditions:
